key: cord-0884875-py1m49tp
authors: Alpert, Orna; Begun, Leonid; Garren, Patrik; Solhkhah, Ramon
title: Cytokine Storm Induced New Onset Depression In Patients With COVID-19. A New Look Into The Association Between Depression and Cytokines -Two Case Reports
date: 2020-11-03
journal: Brain Behav Immun Health
DOI: 10.1016/j.bbih.2020.100173
sha: 61c8d61893f1eef271d749b48d85be820c3857cb
doc_id: 884875
cord_uid: py1m49tp

BACKGROUND: Depression appears to be a common complication in patients during and post–COVID-19 infection. Understanding the mechanism of action of cytokines such as interleukin-6, interleukin-10 and others in depression and in cytokine storm syndrome, the core component of COVID- 19, could shine a new light on future treatment options for both disorders. OBJECTIVE: This review demonstrates the role of interleukins in COVID-19 pathogenesis and their role in depression. RESULTS: We described cases we have treated as an example for the dual role interleukins have in COVID-19 infection and depression and reviewed approximately 70 articles focusing on the role of interleukins in cytokine storm syndrome and depression. CONCLUSION: This review highlights the key features of cytokines in both diseases. As the scientific community has more time to recover and process the effect of the current pandemic, we believe that additional research will pave the way to diverse pathways to treat depression in these patient and others.

The worldwide impact of the COVID-19 pandemic is significant and growing with the escalation of global cases, leading to increased mortality and morbidity of patients who survive (1) . As of October 25, 2020, there have been 42,522,402 total cases worldwide with 1,148,490 deaths (2) . The impact of the pandemic is not only limited to case numbers and mortality rates, but also deeply extends into the mental health of the global population. These cases are further compounded by the psychological pressure stemming from the ever-growing economic concerns (1) .

Studies of patients who were diagnosed with acute respiratory syndrome (SARS) have shown that patients who survived and were discharged from the hospital displayed varying degrees of mental health issues (1) . When we examined survivors of previous infections, it became apparent that they were prone to depression (3), anxiety (4), adjustment disorder (5) and post-traumatic stress disorder (6) . This literature review will analyze the psychiatric impact of COVID-19 infection while referencing the naïve patient population experiencing new onset depressive symptoms, the population with active COVID-19 infection, and the population recovering from COVID-19 infection.

Contemporary literature suggests that new onset depression may be caused by inflammation initiated during the active phase of the COVID-19 infection which results in a cytokine surge (7) . Over the past 2 decades, an increasing amount of literature supports the hypothesis that inflammation contributes to new onset depression (8) . In addition, this hypothesis suggests that the immune system and its response plays a significant role in the pathophysiology of mood disorders.

The patient received azithromycin, steroids, ceftriaxone, magnesium, and terbutaline. The patient began to deteriorate after admission and met criteria for intensive care unit (ICU) admission and intubation due to hypoxic respiratory failure and hypotension. While intubated in the intensive care unit, the patient was treated with fentanyl, midazolam and empiric antibiotic (piperacillin, tazobactam vancomycin). The patient was also treated with hydroxychloroquine 200 mg every 12 hours, azithromycin, tocilizumab, zinc sulfate 220 twice daily to target COVID-19 infection.

The patient's hospital course was complicated by sepsis, seizure like activity with brain dysfunction on EEG consistent with metabolic encephalopathy (delirium) in the context of a negative head CT. The patient began to improve and was extubated on admission day 18. Psychiatry was consulted on admission day 33 to evaluate the patient for depression following suicidal statements. The patient admitted to depression with frequent crying, getting easily frustrated, and demands to leave the hospital against medical advice. He endorsed hopelessness, helplessness, and isolation with a preoccupation on dying. His sleep was poor with difficulty falling asleep and maintaining his sleep. He endorsed poor appetite, anxiety, and panic attacks.

Furthermore, the patient's wife reported that the patient was confused and unable to retain new information. Hospital Anxiety and Depression Scale (HADS) was administered to the patient and he scored 19 on depression (severe) and 16 (severe) on anxiety. For reference, an asymptomatic value on the scale is less than 7 and severe range is 15-21.

The patient was diagnosed with depression disorder according to the Diagnostic and Statistical Manual of Mental Disorder, 5 th Edition (DSM-5). In J o u r n a l P r e -p r o o f accordance to psychiatry's recommendation, the patient began treatment with escitalopram 10 mg daily, later titrated to 20 mg. His insomnia was treated with melatonin with poor response. The patient was temporarily started on mirtazapine 15mg for anxiety and ongoing insomnia which was discontinued once the patient's insomnia and anxiety subsided. The patient then remained on escitalopram 20 mg, moving forward. The patient's inflammatory cytokines (IL-6) level, which were elevated during the first stages of the disease, normalized over time along with the D-dimmer and lymphopenia.

The patient's depressive symptoms subsided approximately 6 weeks following the initiation of treatment with antidepressants and normalization of the inflammatory cytokines. The medications were discontinued while the patient attended rehabilitation. Psychiatry was consulted on admission day 30 to assist with assessment of the patient's mood. The hospital nursing staff observed an increase in anxiety, low mood, withdrawn appearance, and refusing to accept calls from her family. She reportedly made passive suicidal statements such as "I don't want to live anymore." In addition, the patient reported sadness, fatigue, and poor energy and appetite. Patient's granddaughter reported to the nutritionist that patient had made comments regarding decreased appetite, which she believed was due to her being depressed and isolated from family. Hospital Anxiety and Depression Scale (HADS) was administered to the patient and she scored 14 on depression (abnormal/moderate) and 13 (abnormal/mild) on anxiety. As stated previously, asymptomatic value on the scale is less than 7 and severe range is 15-21. Discussions regarding discharge home halted when the patient's conditioned worsened. Her oxygen requirement began to deteriorate, and she became septic due to a pressure wound resulting in mechanical ventilation. She was placed on IV steroids and a feeding tube was inserted. She developed an upper gastrointestinal bleeding which was subsequently stabilized. She received covalence plasma and continued with antidepressant treatment by gastric tube. During the next few days, the patient became hemodynamically unstable and she was found pulseless. (7) . The endemic infection spread rapidly without sparing a continent and became a global pandemic (11) . The mortality rate of critically sick patients is high, approximately 49-61.5 % or higher, 79% (7, 12) .

The SARS-CoV and SARS-CoV-2 use the angiotensin-converting enzyme-related carboxypepetide (ACE2) receptor to gain entry into cells. This receptor was found to be expressed in cardiopulmonary tissues, monocytes, and macrophages (13) . Lymphopenia, a low lymphocyte count in the peripheral blood, is an important feature in COVID-19 infection and is correlated closely with disease severity (13) . It is recognized that SARS-CoV infects primarily human monocytes and dendritic cells J o u r n a l P r e -p r o o f leading to dendritic cell dysfunction resulting in T-cell apoptosis and exhaustion which contribute to the immunopathology (13) . The infection of monocytes, macrophages, and dendrites result in a cascade leading to secretion of IL-6 and other cytokines. COVID-19-infected patients often present with fever, cough, fatigue, shortness of breath, pneumonia diagnosed by imaging, and other respiratory tract symptoms (11) . However, as time progressed, it became apparent that other systems are involved including the CNS, kidneys, gastrointestinal tract, heart, and immune system. It also became evident that while some patients developed mild disease, others developed progressive, fulminate disease ending in death (14). Patients with mild cases show symptoms of fever, dry cough, fatigue, abnormal chest CT findings but with good prognosis. Patients with severe disease are likely to develop acute respiratory distress syndrome (ARDS) and multiple organ failure with death rates ranging from 4.3% to 15% (14). ARDS and multiorgan failure are often the leading cause of death in severely ill patients (7) . Clinical information received from various hospitals indicate that 17.7% to 32% of patients with COVID-19 required ICU care and that the average length of stay was 9.5-12 days. The most common causes for ICU admission were ARDS (67%), acute kidney injury (29%), acute cardiac injury (23%) and liver dysfunction (29%) (7).

Significant clinical data is emerging regarding the manifestation of neuropsychiatric symptoms in COVID-19. Reports originating from China and the U.S

show that close to 50% of patients hospitalized for severe disease exhibited cerebrovascular manifestations such as strokes, encephalitis, and muscle injuries (15) . skeletal muscle injury (16) . Furthermore, those who presented with CNS symptoms such as headaches, dizziness, and ataxia showed low blood lymphocyte count, and patients with myalgia also exhibited an increase in C-reactive protein (CRP) (15) .

were anosmia and ageusia (15) . Prior information from infection with human alphacoronavirus (HC0V-229E) demonstrated disruption of the ciliary nasal epithelium and it is speculated that this may be the mechanism behind SARS-CoV-2. It has also become apparent that olfactory epithelial cells express the angiotensin-converting enzyme 2 (ACE2).

Encephalopathy or delirium (alteration in consciousness) is another CNS manifestation of COVID-19 described in 20% of patients (15) . In those patients "cytokine storm syndrome" (CSS) or "cytokine release syndrome" (CRS) was evident with elevated blood plasma levels of pro-inflammatory cytokines such as Interleukin-6 (IL-6), tumor necrosis factor-a (TNF-a), Interleukin-8 (IL-8), Interleukin-10 (IL-10) and

Interleukin-2R (IL-2R) (14). These patients often present to the hospital with altered mental status as their only symptom and were later found to be COVID-19 positive. The Research indicates that Cytokine Release Syndrome (CRS) often plays a role in severe cases resulting in death (7). We define CRS as an "uncontrolled and overwhelming release of pro-inflammatory mediators by an overly activated immune system (14)." CRS is common in patients with COVID-19, and elevated serum IL-6 is strongly correlated with ARDS, respiratory failure and poor outcome. C-reactive protein (CRP) level is also elevated in patients with COVID-19 and its expression is stimulated by IL-6 (13). Postmortem examinations of deceased patients from the disease revealed elevated inflammatory cytokines, tissue necrosis, and infiltration of intestinal macrophages and monocytes in lungs, heart, gastrointestinal mucosa (7) . Severe lymphopenia with hyperactivated proinflammatory T-cells (7) A link between the development of mood disorder and inflammation with activation of inflammatory response was seen in animal models and humans and has been a focus of interest in recent research (17). When examining the connection between the immunological based disorders and depression, accumulative evidence is seen that implicates the immune system in the pathogenesis of major depression (18) .

High levels of CRP are found in about 25% of patients with depression disorder (18) . In addition to high CRP, the proinflammatory IL-6, its upstream stimulator, has been associated with depressive symptoms such as low mood, increase in appetite, sleep irregularity, low energy, and inability to focus and concentrate (18) . An association was also found between an increased level of inflammatory markers, especially IL-6 and suicidality and it is evident that patients who suffer from chronic inflammatory illness, such as Inflammatory Bowel Disease, tends to exhibit an increased in suicide rate (18) .

This association between IL-6 signaling, depression and suicidality may have clinical importance in managing depression and suicidality. Suicidality can be an additional sign to a high level of CRP seen in inflammatory activity which can be used for immunotherapy for depression and suicide behavior. It can also be helpful for the evaluation of effectiveness of immunotherapy for depression and suicide ideation and behavior (18) . Raison showed in his study that that infliximab, a tumor necrosis factor alpha, was effective in patients with depression and suicidality who had high level of CRP prior to treatment (18, 19) . Studies have shown that in addition to the previous mechanism, microbial products such as lipopolysaccharides (LPS), which leak through the damaged GI tract mucosa or skin, can stimulate secretion of pro-inflammatory cytokines through "Tolllike receptors." The intestinal mucosa is especially vulnerable to injury from TNF-a and it has an important role in amplification and propagation of the cytokines storm typical of J o u r n a l P r e -p r o o f GVHS (22) . In addition, LPS "danger-associated molecular patterns" originated from GI microbiota and have an important role in GVHS (20) .

Recent observational studies have identified that chronic GVHD is a risk factor for depression following an HCT due to the release of pro-inflammatory cytokines, which is seen in other medical conditions accompanied by inflammation such as cancer, autoimmune disease and post viral infections (23) . In GVHD, pro-inflammatory cytokines are able to activate central nervous system circuits leading to neurobehavioral and affective responses such as depressive mood, fatigue, sleep disturbance, anorexia and decrease in cognition, seen in other chronic inflammatory disorders. It is believed that anti-depressant medications have a role in suppressing immune mediated disorders in addition to providing treatment for depression (23) . Furthermore, research also suggests that anti-inflammatory drugs can improve depressive symptoms in patients with chronic inflammatory diseases independent of improvement in the physical illness (18) .

High prevalence of depression is often seen in individuals with immunological diseases such as autoimmune diseases (rheumatoid arthritis and other connective tissue diseases), inflammatory bowel disease, and infections such as COVID-19. The role of inflammation involving C-reactive protein (CRP) and inflammatory cytokines in depression were shown when the improvement in inflammation was evident following treatment with anti-depressants.

In a prospective cohort study consisting of 78 million individuals, Benros at el, demonstrated that infection and autoimmune diseases increase the risk of developing mood disorders. Infection is the most common risk factor occurring in 32% J o u r n a l P r e -p r o o f of patients without a history of depression, while autoimmune disease was represented in only 5% of patients (17). In addition, patients with autoimmune disease who also acquire infection, experience an increased risk of developing depression; more than 4 times the general population (17). When a patient had both infection and autoimmune disease, the risk of mood disorder was compounded (17). It was observed that severe infections are more likely to affect the brain than less severe infections, due to more intense inflammatory response. It was also observed in this study that patients hospitalized for influenza and coronavirus showed mood disorders, especially depression (17, 24). "Sickness behavior," a drastic change in experience and behavior occurring in physically ill patients, which includes a decrease in appetite, apathy, fatigue, impairment in concentration, sleep disturbance and lack of interest in social interaction, can be induced by systemic inflammation. It is a normal response to infection and is characterized by endocrine, autonomic and behavioral changes and is induced by pro-inflammatory cytokines (25) . The clinical presentation of "sickness behavior" is similar to that seen in depression and in vulnerable individuals with prolonged systemic disease (17). However, in addition to "sickness behavior," proinflammatory cytokines can induce true depressive illness in the physically ill patients with no previous history of mental illness (25) .

Inflammation occurring in autoimmune disease and infections are likely to alter the brain due to a compromise of the blood-brain barrier, leading to increase in permeability leaving the brain susceptible to infectious agents and immune components such as cytokines (17).

It is apparent that the pro-inflammatory cytokines affect depression through the tryptophan-Kynurenine-pathway which regulates serotonin production and N-methyl-aspartate glutamate (NMDA) receptor activity (17, 25) . Tryptophan, as an essential ammino acid, is actively transported into the brain for the synthesis of Peripheral blood samples of patients with depression showed an activation of the inflammatory pathways, which was manifested by an increase in proinflammatory cytokines, acute-phase proteins, expression of chemokine and adhesion molecules (26) . The levels of IL-6, IL-8, IL-β, tumor necrosis factor (TNF)-a and CRP were observed to be elevated in the peripheral blood and the central nervous system in patients with depression (26) . Acute-phase proteins such as a-1-acid glycoprotein, a-1-antichymotrypsin and haptoglobin were also present (26).

Patients with depression disorder show an increase in innate immune cytokines and soluble receptors in both their peripheral blood and cerebrospinal fluid (CSF). Evidence suggests an increase in chemokines and adhesion molecules in the peripheral blood as well (27) .

One of the first cytokines that was studied by multiple researchers to understand the connection between cytokines and depression was interferon (IFN)-a. It served as a model for cytokine-induced depression (26) . Approximately, 30-50% of patients treated with interferon IFN-a met criteria of depression (27) . When the cytokine IFN-a was used for the treatment of infectious disease such as hepatitis-C and cancers, patients developed a behavioral syndrome that appeared similar to depression and responded to treatment with antidepressant agents (26) . Symptoms associated with depression disorder include anhedonia, feelings of guilt, suicidal thoughts, anxiety, as well as cognitive symptoms such as loss of concentration, disturbance of memory, difficulty in word finding, confusion, and indecisiveness (27) . Additional depressive neurovegetative symptoms include fatigue, loss of energy, abnormal sleep and appetite, and psychomotor retardation (28) . Some patients may exhibit somatic complaints (28) .

Those symptoms were seen in medically healthy people when the inflammatory system was activated and in patients with cardiovascular disease, cancer, rheumatologic disease, gastrointestinal disease, and post viral infection (26) . IFN-a is a potent inducer of pro-inflammatory cytokines, primarily IL-6 but also IL-1β and TNF-a. It also became apparent that IFN-a is associated with alterations in serotonin metabolism and it has an effect on CRH function by leading to an increase in adrenocorticotropic hormone ACTH and cortisol (26) . (29) . Inflammatory cytokines such as IL-6, and acute base proteins such as CRP, are associated with an increase in depression over time (29) . Symptoms consistent with depression are also associated with T cell activation, which is manifested by an increase in soluble IL-2 receptors (sIL-2Rs), sCD8 concentration, as well as an increased activation of effector T-cell response including increase in IL-2, interferon (IFN)-gamma, and IL-17 (29) . Patients with IBD often experience somatic symptoms of depression more frequently than depressive symptoms. Fatigue is reported by 44-86% of patients with active disease and 22-41% of patients in remission (29) . About 77% of patients with active IBD and 49% of patients with inactive disease reported poor sleep.

In a cross-sectional study of 96 individuals with Crohn's Disease (CD) and healthy controls, an increase in CRP measured by standard sensitivity and increase in erythrocyte sedimentation rate (ESR) were strongly correlated with poor sleep and fatigue.

The use of anti-tumor necrosis factor (TNF) agents changed the outcome of patients with IBD with significant decrease in the need for surgery and complications.

Anti-TNF agents can neutralize soluble TNF but also exert their effect through binding membrane-bound TNF (29) leading to apoptosis in the proinflammatory T lymphocytes, reducing the levels of T-cell-derived proinflammatory cytokines resulting in a decrease in active inflammatory cells in the intestinal mucosa (29) .

In a retrospective study of 69 patients with IBD, a treatment with an anti-TNF showed significant improvement in Patient Health Questionnaire-9 (PHQ-9) depression scores independently of IBD severity symptoms and it was correlated with change in CRP (29) . It was also observed that the use of Vedolizumab improved depression and sleep in patients with IBD (29) . (30) . It became apparent that IL-6 and TNF-a were positively correlated with depressive symptoms. Higher levels of IL-10 were correlated with more depressive symptoms. IL-10 was associated with depression in patients with RA and SLE, but higher levels were measured in RA versus lower level in SLE. It was also found that treatment with IL-6 inhibitor, such as tocilizumab could decrease depressive symptoms and disease activity in RA patients (30) . immunoassay. The study found that serum IL-6 and IL-10 levels were positively correlated to depression disorder but not in healthy control subjects. Further evaluation showed that the increase in IL-6 during depression lead to an induction of IL-10 release (31) . It was also hypothesized that an increase in cytokine level may be related to an increase HPA axis activity as manifested by an increase in cortisol, which normally has an anti-inflammatory effect. However, dysregulated HPA axis seen in depression will result in poor anti-inflammatory effects resulting in an increase in pro-inflammatory cytokines.

It has been known for some time that cytokines, a heterogeneous group of polypeptides, play a key role in the immune activation during states of depression and stress (26) . The cytokines produced and released in the periphery are carried by transport systems to the brain. In the brain, glial cells can produce cytokines, which in turn can affect neurotransmitters, especially monoamines that play important role in depression. Research has shown that the plasma concentration of IL-6 increases one hour after restraint stress and following the initial peak, a gradual and attenuated decrease was seen. Other studies show that the elevation in IL-6 level during stress was independent of the intestinal microflora (32).

Research has investigated the relationship between various types of depression and IL-6. It became evident that patients with melancholic depression characterized by psychomotor retardation, anxiety, loss of appetite and change in sleep pattern, show higher activity of IL-6 compared to healthy control individuals. Patients with melancholic depression also demonstrate higher IL-6 levels that did not normalize despite clinical response to electroconvulsive therapy (ECT). Patients with atypical depression with hypersomnia, increase in appetite and weight gain also demonstrated elevated levels of IL-6. These findings are also found in postpartum depression and dysthymic disorders (33).

Emily Yi-Chith et al investigated the relationship between elevated IL-6 levels in patients with depression and their brain morphology. It was apparent that there is an inverse correlation between the serum IL-6 level and prefrontal cortex thickness.

Sleep disturbance and impairment in sustained attention was positively related to an increase in IL-6 level (34) . Patients with cancers such as lung, ovarian, colorectal, pancreatic, and others show higher levels of IL-6 compared to healthy controls. It was found that improvement in depressive symptoms in these patients was correlated with normalization of IL-6 levels. Symptoms such as anorexia, insomnia, and fatigue were significantly associated with elevated IL-6 levels (34).

The pathogenesis of these phenomena is complicated and multiple mechanisms are involved. It is believed that when encountering a foreign antigen, whether it is a virus, bacteria, or cancer cell, monocyte immune cells secrete cytokines including IL-6. Following the antigen presentation, dendritic cells mature producing cytokines, which stimulate lymphocytes. Due to circulating inflammatory factors, there is J o u r n a l P r e -p r o o f an increase in the blood brain barrier permeability allowing access of the proinflammatory cytokines produced by macrophages and monocytes. The leaky blood brain barrier can lead to access of other microorganisms (31) . Studies have shown that depression responds to treatment with decreasing IL-6 levels. This could be achieved by using IL-6R antibodies (e.g., tocilizumab) or IL-6 antibodies (e.g., sirulumab) (32).

In the two cases we observed in the early phase of the pandemic we found association between depression and cytokines such as IL-6, which are the core components in the cytokine storm syndrome in COVID-19. This was also found by the previous research we reviewed. This association was also seen in chronic medical conditions with inflammatory components such as graft-versus-host disease, autoimmune diseases, inflammatory bowel disease, rheumatoid arthritis, cancer and infections. We observed patients who often developed depression during or postinfection. This mechanism is separate from other mechanisms of depression during this pandemic such as social isolation, psycho-socioeconomic stressors. This suggests that using medications that lower cytokine activity can ameliorate the symptoms of depression, since the normalization of pro-inflammatory cytokines decreased depression with or without anti-depressant treatment.

As the scientific community has more time to recover and process the effects of the current pandemic, we believe that there will be ongoing research that will shine a greater light on the diverse and extensive pathways that can contribute to J o u r n a l P r e -p r o o f depression. Since we observed an association between depression and cytokines such as IL-6, there is a need for additional research to investigate the effects caused by the other interleukins involved in the cytokine storm reaction, to gain further understanding of the process. The cytokine storm is a direct part of the infectious process and its correlation with serotonin and dopamine is well understood.

As the world comes to terms with this current reality, it is important to maintain a multidisciplinary approach in treating the psychological effects of this pandemic. Treatment regimens that can focus on diminishing the effect of the virus from a cytokine perspective can be effective during the acute phase of the disease. However, they do not serve to replace the SSRIs and other standards of treatment that would be effective once the acute inflammatory process subsides and the patients return back to a non-infective state.

When we examined the cases presented, it became apparent that those patients experienced cytokine storm described above. The role of the immune system is to fight various infections, however, an excessive and dysregulated immune response seen in patients affected by COVID-19 contribute to ARDS and multiorgan failure. We observed that those patients presented with high levels of various pro-inflammatory cytokines such as lnterleukin-6, Interleukin-10 and others and chemokines (CCL2, CCL-5). These pro-inflammatory cytokines are elevated in patients with depression and we observe the connection between the two in the patients discussed. Specifically, we observed a resolution of the depression with the decline of pro-inflammatory cytokines with anti-depressant treatment.

J o u r n a l P r e -p r o o f Treatment with tocilizumab and SSRIs anti-depressants in both cases lead to a decrease in the level of cytokines and improvement in depressive symptoms.

Since delirium could have complicated the diagnosis of depression, this was ruled out in our patients through clinical evaluation of the patient and the Mini Mental Status Exam.

Immediate psychological distress in quarantined patients with COVID-19 and its association with peripheral inflammation: A mixedmethod study

Covid-19 dashboard by the center for systems science and engineering(CSSE) at Johns Hopkins University

Within-subject associations between inflammation and features of depression: Using the flu vaccine as a mild inflammatory stimulus

Psychological Predictors of Anxiety in Response to the H1N1 (Swine Flu) Pandemic

The impact of pandemic influenza H1N1 on health-related quality of life: a prospective population-based study

Q-fever-related absence and PTSD in reservists

Can we use interleukin-6 (IL-6) blockade for coronavirus disease 2019 (COVID-19)-induced cytokine release syndrome (CRS)?

Anti-cytokine agents for anhedonia: targeting inflammation and the immune system to treat dimensional disturbances in depression

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Psychiatric complications in patients with severe acute respiratory syndrome (SARS) during the acute treatment phase: a series of 10 cases

Epidemiology and transmission of COVID-19 in 391 cases and 1286 of their close contacts in Shenzhen, China: a retrospective cohort study

Efficacy of glutathione therapy in relieving dyspnea associated with COVID-19 pneumonia: A report of 2 cases

Cytokine release syndrome in severe COVID-19

Longitudinal characteristics of lymphocyte responses and cytokine profiles in the peripheral blood of SARS-CoV-2 infected patients

Are we facing a crashing wave of neuropsychiatric sequelae of COVID-19? Neuropsychiatric symptoms and potential immunologic mechanisms

Neurologic Manifestations of Hospitalized Patients With Coronavirus Disease

Autoimmune diseases and severe infections as risk factors for mood disorders: a nationwide study

Dissecting the association between inflammation, metabolic dysregulation, and specific depressive symptoms: a genetic correlation and 2-sample mendelian randomization study

A randomized controlled trial of the tumor necrosis factor antagonist infliximab for treatment-resistant depression: the role of baseline inflammatory biomarkers

Cytokines in Graft-versus-Host Disease

Cytokine mediators of chronic graft-versus-host disease

Graft-versus-host disease

Depression following graft-versus-host disease in a patient with acute lymphoblastic leukaemia: A case report

Association of seropositivity for influenza and coronoviruses with history of mood disorders and suicide attampts

From inflammation to sickness and depression: when the immune system subjugates the brain

Cytokines sing the blues: inflammation and the pathogenesis of depression

Mechanisms of cytokine-induced behavioral changes: psychoneuroimmunology at the translational interface

Neuroendocrine-immune mechanisms of behavioral comorbidities in patients with cancer

Depressive symptoms in inflammatory bowel disease: an extraintestinal manifestation of inflammation?

Influence of Biological Therapeutics, Cytokines, and Disease Activity on Depression in Rheumatoid Arthritis

Interleukin-6 and Interleukin-10 in mood disorders: A population-based study

Restraint stress elevates the plasma interleukin-6 levels in germ-free mice

Alteration of immune markers in a group of melancholic depressed patients and their response to electroconvulsive therapy

Role of Interleukin-6 in Depressive Disorder

This review highlights the key features of cytokines in both diseases. As the scientific community has more time to recover and process the effect of the current pandemic, we believe that additional research will pave the way to diverse pathways to treat depression in these patient and others

To: Editors Brain, Behavior and Immunity Health. This is to document that there are no conflicts of interest regarding the article submitted for publication.Orna Alpert, M.D.